SPY322.64-7.66 -2.32%
DIA267.58-5.23 -1.92%
IXIC10,632.99-330.65 -3.02%

PTC Therapeutics Receives $20M Milestone Payment From Roche Under License And Collaboration Agreement

SOUTH PLAINFIELD, N.J., Aug. 26, 2020 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that the company achieved a $20 million milestone payment from Roche under its License and

 · 

SOUTH PLAINFIELD, N.J., Aug. 26, 2020 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that the company achieved a $20 million milestone payment from Roche under its License and Collaboration Agreement. The milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the U.S. Evrysdi™ was approved by the Food and Drug Administration (FDA) on Aug. 7, for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older.